Abstract:Doxorubicin (DOX) is the most widely used anthracycline family chemotherapeutic drug in clinical practice. In order to study whether Visnagin (VIS) could alleviate DOX-induced hepatotoxicity and nephrotoxicity and its related mechaninsms, this study first constructed a DOX-induced mouse model with acute or chronic liver and kidney injury. Then the protective effect of VIS on liver and kidney injury was evaluated by observing the mortality of mouse liver and kidney cells and the changes of liver and kidney function. The TUNEL results showed that VIS can significantly reduced apoptosis of liver and cells in acute and chronic injury models, and VIS can also relieve liver and kindey damage in the chronic model, in which VIS reduced DOX-induced creatine / urea and ALT/AST levels. In addition, VIS significantly inhibit the formation of the TOP2-DNA covalent complex level induced by DOX, suggesting that VIS may have a protective effect by inhibiting the TOP2 pathway downstream of DOX. The results will shed light on the follow-up in-depth exploration of reducing the side effects of DOX.
ICP: